Moderna マネジメント
マネジメント 基準チェック /24
Modernaの CEO はStéphane Bancelで、 Oct2011年に任命され、 の在任期間は 14.58年です。 の年間総報酬は$ 19.93Mで、 8.4%給与と91.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の5.54%を直接所有しており、その価値は$ 1.00B 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と12年です。
主要情報
Stéphane Bancel
最高経営責任者
US$19.9m
報酬総額
| CEO給与比率 | 8.42% |
| CEO在任期間 | 14.6yrs |
| CEOの所有権 | 5.5% |
| 経営陣の平均在職期間 | 5.8yrs |
| 取締役会の平均在任期間 | 12yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 13
MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome
Narrative Update on Moderna Analysts have collectively raised their Moderna price targets by low to mid single digit dollar amounts, citing updated models that reflect recent litigation settlements, FDA progress on the flu vaccine, and oncology pipeline developments. Together, these factors support a lower fair value estimate of $66.29, a slightly higher discount rate of 7.21%, adjusted revenue growth expectations of 52.59%, a profit margin of 4.12%, and a future P/E assumption of 107.40x.Seeking Alpha • May 12
Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell
Summary Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets. RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and strategic pivots. Combination mRNA vaccines like mCOMBRIAX offer regulatory progress but commercial success remains uncertain amid persistent vaccine fatigue. Personalized cancer vaccines may leverage mRNA speed but face margin, scalability, and regulatory hurdles, limiting their financial upside for MRNA. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 27
MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside
Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple. Analyst Commentary Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine.
ナラティブの更新 • Apr 13
MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside
Analysts have nudged Moderna's average price target higher by $5, reflecting a mix of renewed confidence in the company's vaccine pipeline after the FDA's reconsideration of its flu shot application and reduced litigation overhang following recent settlement developments. Analyst Commentary Recent research on Moderna clusters around two main themes for you to watch closely: valuation reset around the vaccine pipeline and lingering legal and execution risks tied to the COVID and flu franchises.ナラティブの更新 • Mar 30
MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside
Analyst price targets for Moderna have generally shifted higher, with several firms moving into a $30 to $69 range as they factor in the recent Arbutus settlement, the FDA’s renewed review of the mRNA-1010 flu vaccine with an August 5 PDUFA date, and updated product and oncology pipeline assumptions. Analyst Commentary Street research on Moderna currently reflects a mixed but generally cautious stance, even as litigation and regulatory headlines have reduced some overhangs.ナラティブの更新 • Mar 16
MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside
Analysts have trimmed Moderna's implied fair value from $15.00 to $12.00 as they factor in a higher discount rate, more moderate profit margins and updated views on revenue growth following recent litigation settlements and regulatory updates. Analyst Commentary Street research around Moderna centers on two themes that matter for you as an investor: the clean-up of legal overhangs and how much confidence to place in the broader vaccine and oncology pipeline.ナラティブの更新 • Mar 02
MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision
Our fair value estimate for Moderna has inched up by about $1.65 per share to $91.97 as analysts update their models around higher projected product sales, a more constructive FDA review path for the mRNA-1010 flu vaccine with an August 5 PDUFA date, and refreshed views on the broader late stage pipeline including oncology. Analyst Commentary Street research on Moderna has leaned more constructive around the updated regulatory path for flu vaccine mRNA-1010, the broader late stage pipeline, and recent quarterly disclosures.分析記事 • Feb 17
Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90
As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest annual results with some very strong...ナラティブの更新 • Feb 16
MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes
Analysts have nudged their average price target for Moderna higher by about $3, reflecting updated views on long term revenue potential, profit margins and a higher future P/E multiple following recent research on COVID demand, the broader vaccine pipeline and legal outcomes. Analyst Commentary Recent Street research on Moderna highlights a mix of caution and growing optimism, with several bullish analysts adjusting their models after company updates, legal developments and new financing disclosures.分析記事 • Feb 02
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Despite an already strong run, Moderna, Inc. ( NASDAQ:MRNA ) shares have been powering on, with a gain of 43% in the...ナラティブの更新 • Feb 01
MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside
The analyst price target for Moderna has increased by about $2 to $38.80, as analysts incorporate updated assumptions for slightly stronger revenue growth, modestly better profit margins, a marginally lower discount rate, and a slightly reduced future P/E multiple. Analyst Commentary Recent Street research on Moderna shows a mix of cautious optimism and ongoing concern.ナラティブの更新 • Jan 18
MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential
Narrative update We trim our analyst price target for Moderna from about US$121 to roughly US$87 as analysts factor in lower profit margin expectations, a higher discount rate, cautious views on COVID-related revenue visibility, and a more binary risk profile around key late stage vaccine data, even as some models reflect higher revenue growth assumptions and updated financing terms. Analyst Commentary Recent Street research on Moderna points to a mixed backdrop, with several firms reaffirming cautious stances while still recognizing specific areas where execution and funding choices could support long term value creation.ナラティブの更新 • Jan 04
MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation
Analysts have modestly lifted their price targets on Moderna, with recent revisions such as $15 to $18, $16 to $17, and $32 to $30. These changes collectively reflect slightly improved conviction in the company’s long term revenue growth, gross margin expansion, and strengthened liquidity following new Ares financing, despite ongoing profitability and litigation risks.ナラティブの更新 • Dec 21
MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks
Analysts have modestly raised their price target on Moderna to align with a slightly higher fair value estimate of about $36.75, citing incremental improvements in long term revenue growth and profitability assumptions supported by recent Investor and Analyst Day updates, revised 2026 to 2028 guidance, and Ares financing. Analyst Commentary Recent Street research reflects a cautious but incrementally more constructive stance toward Moderna, with several firms refining their models following Investor and Analyst Day presentations and the announcement of new financing.分析記事 • Dec 19
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise
Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 28% share price jump in the last...ナラティブの更新 • Dec 07
MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk
Analysts have modestly lowered their price target on Moderna to about $35.78 from $37.32 per share, reflecting slightly softer long term growth and valuation assumptions. This comes even as recent Investor and Analyst Day updates, new debt financing and evolving oncology data support a more stable cash outlook and gradual margin improvement.ナラティブの更新 • Nov 23
MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts
Analysts have revised their fair value estimate for Moderna down from approximately $40.30 to $37.32. They cited the company’s updated revenue growth projections and cost outlook, despite improvements in profit margins and continued progress across its commercial and research pipelines.ナラティブの更新 • Nov 07
MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties
Moderna's analyst price target was reduced from $18 to $15, as analysts pointed to lower US vaccination trends and ongoing regulatory uncertainties that are impacting the outlook for its vaccine franchises. Analyst Commentary Recent analyst notes have reflected both cautious and optimistic perspectives on Moderna's outlook.ナラティブの更新 • Oct 23
Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts
Moderna’s analyst price target has been revised downward from $44.25 to $40.30. Analysts cite lower projected revenue growth along with persistent regulatory and profitability challenges, which have been reflected in recent industry commentary.ナラティブの更新 • Sep 04
Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential
Moderna’s consensus price target was held at $44.25 as analysts cited declining US vaccine demand, increased regulatory hurdles for flu/COVID combinations, delayed UK deliveries impacting 2025 guidance, and persistent uncertainty around mRNA vaccine approvals. Analyst Commentary Lowered US vaccination trends for both COVID and flu are reducing addressable market expectations for Moderna’s vaccines.分析記事 • Jul 18
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 26% share price jump in the last...新しいナラティブ • May 02
MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK
Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing andSeeking Alpha • Apr 22
More Downside For Moderna Before The Breakthrough
Summary Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires investor patience, with key vaccines in Phase 3 trials but regulatory approvals potentially years away. Financials are sound enough to support long term research, with a significant cash buffer, but oncology research faces regulatory and technical challenges. Shares are likely to go down before any uptrend (2-3 years horizon). Read the full article on Seeking AlphaSeeking Alpha • Mar 31
FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)
Summary Moderna's stock dropped over 10% after the FDA's Dr. Peter Marks resigned, signaling potential increased regulatory scrutiny on vaccines. Moderna's financial health remains strong, with ~$9 billion in cash and investments, but the stock is down 65% since my August rating downgrade. Despite pipeline progress, regulatory uncertainty and intense competition from Pfizer and GSK pose significant risks to Moderna's revenue outlook. Given the negative public perception of mRNA technology and regulatory risks, I downgrade MRNA to "Hold" until more clarity emerges. Read the full article on Seeking AlphaSeeking Alpha • Mar 06
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Summary Moderna, Inc.'s stock surged 16% yesterday after a German court ruled Pfizer and BioNTech may have violated Moderna's COVID-19 vaccine patent, potentially leading to compensation. Despite the ruling, Pfizer and BioNTech will appeal, while previous court decisions have invalidated related patents, complicating Moderna's legal victory. MRNA's business struggles post-pandemic, with declining revenues and few new products, have made litigation a potentially critical revenue source, which I'd call a red flag. The ongoing legal battles resemble other prolonged patent disputes, highlighting the challenges in monetizing groundbreaking technologies like mRNA and CRISPR. If Moderna had released ten products since 2022, instead of one, it's unlikely yesterday's news would have moved its share price, but this reflects the new reality of messenger-RNA, a technology that hasn't lived up to the hype — yet. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
Moderna, Inc.: Working Hard But Competition Is Working Harder
Summary MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition. Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Read the full article on Seeking Alpha
新しいナラティブ • Feb 09
Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks
Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.Seeking Alpha • Feb 03
Moderna: The Good News Isn't Enough
Summary I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock. I argue why I don't think anything has changed materially, reinforcing my SELL rating. Despite cost-cutting measures, I am concerned that reducing R&D will hurt Moderna's research capabilities, preferring cuts in SG&A instead. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)
Summary Moderna's stock is down 36.63% due to poor COVID-19 vaccine sales and lack of promising alternatives, but bird flu presents asymmetric upside potential. The company's cost-cutting measures may hinder innovation, but rising COVID cases and bird flu risks could uniquely benefit Moderna if a pandemic occurs. Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads significantly. With only a 5% chance of a bird flu pandemic, I believe Moderna is a hold, awaiting further developments on the bird flu's virality. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Moderna: 2025 Contrarian Play
Summary Moderna ends 2024 as one of the worst-performing Nasdaq-100 stocks, but it presents a contrarian play for 2025 due to vaccine catalysts. The stock is down to $40 with a $15 billion market cap, despite having $3+ billion in revenue and a promising pipeline. Moderna's spending issue is a concern, but the potential of its CMV and cancer vaccines could significantly boost sales and justify current R&D expenses. Investors should consider buying the beaten-down stock around $40, anticipating higher sales and multiple big approvals in the coming years. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Moderna: Cutting Costs Might Not Be Enough
Summary Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. MRNA has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. Read the full article on Seeking AlphaSeeking Alpha • Nov 22
Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
Summary Moderna, Inc.'s stock has plummeted over 75% in 2024, driven by disappointing earnings, reduced revenue forecasts, and now the threat of a vaccine skeptic, RFK Jr.'s potential confirmation to lead HHS. Despite two commercialized vaccines and positive Phase 3 results for others, Moderna faces uncertainty in achieving profitability before 2028, with significant R&D expenses and competitive pressures. The private COVID-19 vaccine market is considered stable but limited, and the RSV vaccine faces competition from GSK and Pfizer, and likely restriction to a once-every 3-year dose. A potential acquisition by a Big Pharma like Merck could bring fresh R&D perspectives, but Moderna may need to consider further program cuts to achieve profitability in a shorter time-frame. Read the full article on Seeking AlphaSeeking Alpha • Oct 22
Moderna: Assessing The Impact Of GSK's Patent Lawsuit
Summary GSK's lawsuit against Moderna over lipid nanoparticle technology could severely impact Moderna's revenue from Spikevax and mResvia, and delay their breakeven point. The lawsuit adds uncertainty to MRNA's already declining stock, increasing short-selling activity and potentially leading to prolonged negative headlines. Despite the legal risks, I plan to trade MRNA, looking for a reversion play if the ticker breaks its downtrend with elevated volume. I am lowering my MRNA conviction level from 3 to 2 out of 5 and moving it to the speculative “Bio Boom” portfolio. Read the full article on Seeking AlphaSeeking Alpha • Sep 20
Moderna: Still Bullish View
Summary Moderna's stock has fallen due to the weak management revenue guidance, but I remain positive about its long-term potential. Key developments include the next-gen COVID-19 vaccine, the RSV vaccine, and promising pipeline drugs like the cytomegalovirus and cancer vaccines. Management's 2024 revenue guidance is conservative. I expect Moderna to outperform it. My fair valuation of Moderna stock was adjusted to $149. Read the full article on Seeking AlphaSeeking Alpha • Sep 12
Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling
Summary Moderna, Inc. plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs, leading to a pre-market stock drop of over 13%. Despite pledging 10 product approvals by 2027, falling COVID-19 vaccine sales and increased competition cast doubt on achieving a >25% CAGR. MRNA's financial outlook remains bleak, with expected losses through 2024 and speculative rather than concrete market opportunities for its late-stage pipeline assets. Short-to-medium term downside is likely, though long-term potential remains if new vaccines, like a COVID/flu combo or CMV, succeed. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Summary Moderna, Inc.'s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Pfizer/BioNTech's combination vaccine faced setbacks, giving Moderna a potential advantage in the market. The market for Moderna's RSV vaccine may be limited due to updated CDC recommendations. Moderna's oncology pipeline, including mRNA-4157/V940, shows promise but remains in the early stages. Despite short-term challenges, Moderna's combination vaccine could lead to long-term market outperformance. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$3b |
| Dec 31 2025 | US$20m | US$2m | -US$3b |
| Sep 30 2025 | n/a | n/a | -US$3b |
| Jun 30 2025 | n/a | n/a | -US$3b |
| Mar 31 2025 | n/a | n/a | -US$3b |
| Dec 31 2024 | US$20m | US$2m | -US$4b |
| Sep 30 2024 | n/a | n/a | -US$2b |
| Jun 30 2024 | n/a | n/a | -US$6b |
| Mar 31 2024 | n/a | n/a | -US$6b |
| Dec 31 2023 | US$17m | US$2m | -US$5b |
| Sep 30 2023 | n/a | n/a | -US$3b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$5b |
| Dec 31 2022 | US$19m | US$1m | US$8b |
| Sep 30 2022 | n/a | n/a | US$12b |
| Jun 30 2022 | n/a | n/a | US$14b |
| Mar 31 2022 | n/a | n/a | US$15b |
| Dec 31 2021 | US$18m | US$990k | US$12b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$3b |
| Mar 31 2021 | n/a | n/a | US$598m |
| Dec 31 2020 | US$13m | US$946k | -US$747m |
| Sep 30 2020 | n/a | n/a | -US$597m |
| Jun 30 2020 | n/a | n/a | -US$488m |
| Mar 31 2020 | n/a | n/a | -US$505m |
| Dec 31 2019 | US$9m | US$921k | -US$514m |
報酬と市場: Stéphaneの 総報酬 ($USD 19.93M ) は、 US市場 ($USD 14.80M ) の同規模の企業の平均を上回っています。
報酬と収益: Stéphaneの報酬は増加しましたが、会社は利益を上げていません。
CEO
Stéphane Bancel (52 yo)
14.6yrs
在職期間
US$19,932,217
報酬
Mr. Stéphane Bancel, M.B.A., is Director at Commonwealth Fusion Systems LLC since January 2026. He served as a Board Director at Indigo Agriculture Inc since 2020 until July 2025. Mr Bancel served as an In...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 14.6yrs | US$19.93m | 5.54% $ 1.0b | |
| President | no data | US$18.05m | 0.41% $ 74.7m | |
| Chief Financial Officer | 3.7yrs | US$5.86m | 0.015% $ 2.6m | |
| Chief Legal Officer & Corporate Secretary | 4.9yrs | US$5.40m | 0.017% $ 3.0m | |
| Chief Technical Operations & Quality Officer | 3.3yrs | データなし | データなし | |
| Senior VP & Head of Investor Relations | 7.1yrs | データなし | データなし | |
| Chief People & Digital Technology Officer | 6.6yrs | データなし | データなし | |
| Senior VP & Head of Global Regulatory Science | 6.1yrs | データなし | データなし | |
| Senior Vice President of Commercial Vaccines | 5.9yrs | データなし | データなし | |
| Senior Vice President of Government Engagement | 5.8yrs | データなし | データなし | |
| Chief Safety Officer | 5.3yrs | データなし | データなし | |
| Head of Corporate Security | no data | データなし | データなし |
5.8yrs
平均在職期間
51.5yo
平均年齢
経験豊富な経営陣: MRNAの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 15.2yrs | US$19.93m | 5.54% $ 1.0b | |
| Executive Director | no data | データなし | データなし | |
| Co-Founder | 16.3yrs | US$658.42k | 0.56% $ 101.7m | |
| Independent Director | 5.8yrs | US$563.28k | 0.0012% $ 217.7k | |
| Member of Scientific Advisory Board | no data | US$538.40k | データなし | |
| Member of Technology Advisory Board | 12yrs | データなし | データなし | |
| Independent Director | 5.2yrs | US$543.29k | 0.0049% $ 883.5k | |
| Member of Technology Advisory Board | 12yrs | データなし | データなし | |
| Independent Non Executive Director | 6.4yrs | US$583.27k | 0.0083% $ 1.5m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Chairman of Scientific Advisory Board | 12yrs | データなし | データなし | |
| Member of Technology Advisory Board | 12yrs | データなし | データなし |
12.0yrs
平均在職期間
66yo
平均年齢
経験豊富なボード: MRNAの 取締役会 は経験豊富で 経験豊富 です ( 12年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 03:13 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Moderna, Inc. 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。45
| アナリスト | 機関 |
|---|---|
| null null | Argus Research Company |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |